RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
  Bone Cancer
  Breast Cancer
  Cervical Cancer
  Gastric Cancer
  Liver Cancer
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Testicular Cancer
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Melanoma Channel

subscribe to Melanoma newsletter
Latest Research : Cancer : Skin : Melanoma

   EMAIL   |   PRINT
Clinical Trials Tests CpG7909 and Melan-A Combination Melanoma Cancer Vaccines

Mar 18, 2005 - 4:38:00 PM
It was observed that the majority of T-cell responses developed rapidly with T-cell frequencies peaking seven to ten days after vaccination.

[RxPG] Results from the first Phase 1 clinical trial of a vaccine composed of a synthetic bacterial sequence, CpG7909 (ProMune TM , Coley Pharmaceuticals), and a melanoma antigen, Melan-A, indicate that this vaccine combination is not only safe but also can improve and bolster immune responses to tumors.

Lead authors and members of the Cancer Vaccine Collaborative, Drs. Daniel E. Speiser and Pedro Romero and their team from the Lausanne Branch of the Ludwig Institute for Cancer Research at the Lausanne University Hospital, Lausanne, Switzerland, reported their promising findings in The Journal of Clinical Investigation. In the clinical trial, the eight melanoma patients who each received four monthly injections of the vaccination all exhibited a strong antigen-specific T-cell response, with a rapid increase in the frequency of Melan-A specific T cells.

These T-cell clones recognize and kill melanoma cells in an antigen-specific manner. It was observed that the majority of T-cell responses developed rapidly with T-cell frequencies peaking seven to ten days after vaccination. Future studies will explore if increased doses of CpG7909 and/or peptides can further enhance the observed T-cell activation.

Publication: The Journal of Clinical Investigation
On the web: http://www.jci.org/ 

Advertise in this space for $10 per month. Contact us today.

Related Melanoma News
Compounds extracted from vegetables help to inhibit melanoma
MicroRNA responsible for aggressiveness of metastatic melanoma cell lines
A novel designer molecule to fight malignant melanoma
Listening to the sound of skin cancer
Malignant melanoma cells secrete a potent embryonic growth factor
New mouse model technology in Melanoma vaccine tool-box
Malignant melanoma cells reprogrammed !
New option for patients with metastatic melanoma
Positive family history increases risk of multiple primary melanomas
Role of Slug Gene in Melanoma Metastasis Identified

Subscribe to Melanoma Newsletter

Enter your email address:

For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)